RxDoctor Payments Data

Oluwaseun Adeola

Clinical Cardiac Electrophysiology · Iowa City, IANPI 1518306463

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (34.2%), grants and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 69.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $23,916 and has fallen 88.2% since, to $2,828 in 2025.

$48,541in general payments, 2019–2025

Across 284 payments — averaging $170.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$34K
  • Biotronik Inc.$7K
  • Boston Scientific$3K
  • Biosense Webster, Inc.$2K
  • Abbott$2K
  • Acutus Medical, Inc.$289
  • plus $908 from 9 others

What the payments were for

  • Consulting fees$7812%
  • Speaking & faculty fees$8,05017%
  • Grants$12,50026%
  • Travel & lodging$16,58434%
  • Food & beverage$10,30721%
  • Education$3191%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,541 in reported general payments places this provider in the 85th percentile of 42 clinical cardiac electrophysiology providers in Iowa.

See all clinical cardiac electrophysiology providers in Iowa

Medicare billing

Part B allowed, 2024
$394,322
Medicare patients
1,161
Services billed
4,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban309$380,918
XareltoRivaroxaban49$68,880
MultaqDronedarone Hcl12$15,188
Dofetilide87$9,641
Flecainide Acetate174$6,449
Amiodarone Hcl107$4,299
Metoprolol Succinate164$2,632
SotalolSotalol Hcl84$1,476
Sucralfate37$1,048
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$950
Omeprazole68$839
Midodrine Hcl11$733
ClopidogrelClopidogrel Bisulfate53$658
Torsemide16$648
Amlodipine Besylate79$384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$380,918309 claims
Johnson & JohnsonXarelto$250$68,88049 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 42 clinical cardiac electrophysiology providers in Iowa.

Other clinical cardiac electrophysiology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →